233 related articles for article (PubMed ID: 15462695)
21. Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy.
Cushman WC; Neutel JM; Saunders E; Bakris GL; Ferdinand KC; Ofili EO; Sowers JR; Madder R; Weber MA
Am J Geriatr Cardiol; 2008; 17(1):27-36. PubMed ID: 18174757
[TBL] [Abstract][Full Text] [Related]
22. [Microalbuminuria in patients with hypertension and cardiovascular comorbidity, REAL observational study of treatment with Irbesartan/HCTZ].
Tschöpe C; Tschöpe R; Unger T
MMW Fortschr Med; 2006 Jun; 148(25):48. PubMed ID: 16859162
[No Abstract] [Full Text] [Related]
23. Candesartan cilexetil 32 mg/hydrochlorothiazide 25 mg in unselected patients with high or very high cardiovascular risk: efficacy, safety, and metabolic impact.
Bramlage P; Buhck H; Zemmrich C
Clin Drug Investig; 2014 Apr; 34(4):241-9. PubMed ID: 24482018
[TBL] [Abstract][Full Text] [Related]
24. [Effect of anti-hypertensive therapy with irbesartan on the absolute cardiovascular risk].
Coca A; Ruilope LM; Calvo C; de la Sierra A; Aranda P; Luque M; Marín-Iranzo R;
Rev Clin Esp; 2003 Apr; 203(4):183-8. PubMed ID: 12681201
[TBL] [Abstract][Full Text] [Related]
25. Fixed-dose combination of zofenopril plus hydrochlorothiazide vs. irbesartan plus hydrochlorothiazide in hypertensive patients with established metabolic syndrome uncontrolled by previous monotherapy. The ZAMES study (Zofenopril in Advanced MEtabolic Syndrome).
Napoli C; Omboni S; Borghi C;
J Hypertens; 2016 Nov; 34(11):2287-97. PubMed ID: 27653164
[TBL] [Abstract][Full Text] [Related]
26. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Lewis EJ; Lewis JB
Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
[TBL] [Abstract][Full Text] [Related]
27. Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus.
Mugellini A; Preti P; Zoppi A; Corradi L; Fogari E; Derosa G; Fogari R
J Hum Hypertens; 2004 Oct; 18(10):687-91. PubMed ID: 15071488
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of irbesartan/HCTZ in severe hypertension according to cardiometabolic factors.
Franklin SS; Neutel JM
J Clin Hypertens (Greenwich); 2010 Jul; 12(7):487-94. PubMed ID: 20629810
[TBL] [Abstract][Full Text] [Related]
29. Microalbuminuria in hypertensive patients: evaluation of one-year treatment with irbesartan.
de Alvaro F; Velasco O; Honorato J; Calvo C; Parrondo I;
Kidney Int Suppl; 2005 Jan; (93):S29-34. PubMed ID: 15613064
[TBL] [Abstract][Full Text] [Related]
30. Effect of amlodipine, efonidipine, and trichlormethiazide on home blood pressure and upper-normal microalbuminuria assessed by casual spot urine test in essential hypertensive patients.
Hosaka M; Inoue R; Satoh M; Watabe D; Hanazawa T; Ohkubo T; Asayama K; Obara T; Imai Y;
Clin Exp Hypertens; 2018; 40(5):468-475. PubMed ID: 29172732
[TBL] [Abstract][Full Text] [Related]
31. [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on Irbesartan or Irbesartan/HCTZ].
Schmieder RE; Krekler M
MMW Fortschr Med; 2005 Aug; 147(31-32):43. PubMed ID: 16128197
[No Abstract] [Full Text] [Related]
32. The efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed-dose combination in hypertensive patients with and without high cardiovascular risk.
Weir MR; Neutel JM; Bhaumik A; De Obaldia ME; Lapuerta P
J Clin Hypertens (Greenwich); 2007 Dec; 9(12 Suppl 5):23-30. PubMed ID: 18046109
[TBL] [Abstract][Full Text] [Related]
33. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations.
Bobrie G; Delonca J; Moulin C; Giacomino A; Postel-Vinay N; Asmar R;
Am J Hypertens; 2005 Nov; 18(11):1482-8. PubMed ID: 16280286
[TBL] [Abstract][Full Text] [Related]
34. The KARTAN study: a postmarketing assessment of Irbesartan in patients with hypertension.
Morales-Olivas FJ; Arístegui I; Estañ L; Rodicio JL; Moreno A; Gil V; Ferrón G; Velasco O;
Clin Ther; 2004 Feb; 26(2):232-44. PubMed ID: 15038946
[TBL] [Abstract][Full Text] [Related]
35. Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension.
Neutel JM; Franklin SS; Bhaumik A; Lapuerta P; Oparil S
Clin Exp Hypertens; 2009 Oct; 31(7):572-84. PubMed ID: 19886855
[TBL] [Abstract][Full Text] [Related]
36. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
Rizos CV; Milionis HJ; Kostapanos MS; Florentin M; Kostara CE; Elisaf MS; Liberopoulos EN
Clin Ther; 2010 Mar; 32(3):492-505. PubMed ID: 20399986
[TBL] [Abstract][Full Text] [Related]
37. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria.
Andersen S; Bröchner-Mortensen J; Parving HH;
Diabetes Care; 2003 Dec; 26(12):3296-302. PubMed ID: 14633817
[TBL] [Abstract][Full Text] [Related]
38. Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy.
Ofili EO; Ferdinand KC; Saunders E; Neutel JM; Bakris GL; Cushman WC; Sowers JR; Weber MA
J Natl Med Assoc; 2006 Apr; 98(4):618-26. PubMed ID: 16623075
[TBL] [Abstract][Full Text] [Related]
39. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.
Gradman AH; Schmieder RE; Lins RL; Nussberger J; Chiang Y; Bedigian MP
Circulation; 2005 Mar; 111(8):1012-8. PubMed ID: 15723979
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan.
Gialama F; Maniadakis N
Vasc Health Risk Manag; 2013; 9():575-92. PubMed ID: 24124375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
